NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

SPRO

Spero Therapeutics Inc

Jul 07 • 04:00PM ET

2.90

Dollar change -0.01
Percentage change -0.34	%

Healthcare • Biotechnology • USA • NASD

Peers: AVIR CDTX AMRX TVRD ANIP CBIO DSGN FENC CSBR HURA

| Held by: VTI VXF QQQS AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.28	Insider Own	33.45%	Shs Outstand	55.90M	Perf Week	-1.36%
Market Cap	162.14M	Forward P/E	-	EPS next Y	-1.63	Insider Trans	-1.59%	Shs Float	37.21M	Perf Month	9.02%
Enterprise Value	117.21M	PEG	-	EPS next Q	-0.38	Inst Own	20.66%	Short Float	4.33%	Perf Quarter	364.74%
Income	-69.76M	P/S	5.73	EPS this Y	9.45%	Inst Trans	-4.80%	Short Ratio	0.38	Perf Half Y	181.55%
Sales	28.30M	P/B	4.79	EPS next Y	-41.74%	ROA	-56.85%	Short Interest	1.61M	Perf YTD	181.55%
Book/sh	0.60	P/C	3.32	EPS next 5Y	7.97%	ROE	-107.28%	52W High	3.09 -6.15%	Perf Year	122.22%
Cash/sh	0.87	P/FCF	-	EPS past 3/5Y	24.13% 17.67%	ROIC	-193.90%	52W Low	0.51 474.03%	Perf 3Y	260.65%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	107.42% 8.59%	Gross Margin	-	Volatility	2.48% 5.68%	Perf 5Y	-78.11%
Dividend TTM	-	EV/Sales	4.14	EPS Y/Y TTM	-390.00%	Oper. Margin	-315.65%	ATR (14)	0.16	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.56	Sales Y/Y TTM	-71.75%	Profit Margin	-246.49%	RSI (14)	70.81	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.56	EPS Q/Q	-5.79%	SMA20	1.05%	Beta	1.41	Target Price	5.00
Payout	-	Debt/Eq	0.12	Sales Q/Q	21.57%	SMA50	60.87%	Rel Volume	0.20	Prev Close	2.91
Employees	32	LT Debt/Eq	0.06	Earnings	May 13 AMC	SMA200	140.98%	Avg Volume	4.26M	Price	2.90
IPO	Nov 02, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	54.55% -46.60%	Trades		Volume	844,733	Change	-0.34%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line	$5
Sep-23-22	Upgrade	Evercore ISI	In-line → Outperform	$2 → $8
Oct-01-21	Downgrade	Oppenheimer	Outperform → Perform
Jan-22-21	Reiterated	H.C. Wainwright	Buy	$33 → $40
Dec-16-20	Initiated	Berenberg	Buy	$47
Sep-29-20	Initiated	Evercore ISI	Outperform
Nov-05-19	Reiterated	H.C. Wainwright	Buy	$28 → $35
Sep-09-19	Initiated	Janney	Buy
Feb-09-18	Initiated	Cantor Fitzgerald	Overweight	$27
Nov-27-17	Initiated	Stifel	Buy	$26
Nov-27-17	Initiated	Oppenheimer	Outperform	$30
Nov-27-17	Initiated	BofA/Merrill	Neutral	$16

Show Previous Ratings

Jul-04-25 08:35AM	AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer (Zacks)
Jul-02-25 08:34AM	Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek (Zacks)
Jul-01-25 11:55AM	RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance (Zacks)
10:05AM	ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B (Zacks)
Jun-30-25 10:40AM	Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why (Zacks)
01:15PM	Loading…
May-29-25 01:15PM	Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone (Insider Monkey) -9.36%
11:18AM	SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal (Zacks)
May-28-25 07:00AM	GSK-licensed antibiotic meets goal in late-stage study (BioPharma Dive) +244.57%
07:00AM	Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee (GlobeNewswire)
May-13-25 05:10PM	Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +13.11% -5.78%
04:01PM	Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update (GlobeNewswire)
May-12-25 09:53AM	Spero Therapeutics Inc (SPRO) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
May-09-25 08:20AM	UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +7.83%
May-08-25 05:55PM	Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-07-25 05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Loading…
May-05-25 08:00AM	Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 (GlobeNewswire) -5.72%
Apr-28-25 04:01PM	Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer (GlobeNewswire) -5.49%
Mar-28-25 07:10AM	Q4 2024 Spero Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -10.88%
03:03AM	Spero Therapeutics Inc (SPRO) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges ... (GuruFocus.com)
Mar-27-25 08:31PM	Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript (Seeking Alpha)
05:20PM	Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update (GlobeNewswire)
Mar-18-25 08:00AM	Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025 (GlobeNewswire)
Feb-25-25 10:15AM	UPDATE Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
07:00AM	Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-15-25 12:00PM	Spero Therapeutics (SPRO) Upgraded to Buy: Here's What You Should Know (Zacks) -7.90%
Jan-10-25 07:00AM	Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes (GlobeNewswire)
Dec-16-24 06:34PM	Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-18-24 12:09PM	TenNors Phase III antibiotic trial meets all primary endpoints (Clinical Trials Arena)
Nov-14-24 05:35PM	Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -5.60%
04:05PM	Loading…
04:05PM	Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update (GlobeNewswire)
Nov-13-24 07:29AM	What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 Earnings (GuruFocus.com)
Nov-07-24 04:05PM	Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024 (GlobeNewswire)
Oct-30-24 08:45AM	Speros stock slides after antibiotic flops in Phase II trial (Pharmaceutical Technology)
Oct-29-24 04:05PM	Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update (GlobeNewswire)
Oct-16-24 04:05PM	Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024 (GlobeNewswire)
Oct-02-24 04:30PM	Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy (GlobeNewswire)
Sep-04-24 04:05PM	Spero Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-06-24 07:51AM	Q2 2024 Spero Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -5.22%
Aug-05-24 08:59PM	SPRO Stock Earnings: Spero Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:35PM	Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update (GlobeNewswire)
Jul-29-24 04:05PM	Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024 (GlobeNewswire)
Jul-08-24 03:07PM	3 Micro-Cap Moonshots for Fearless Investors (InvestorPlace)
Jul-03-24 01:05PM	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-24 04:05PM	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-16-24 04:05PM	Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference (GlobeNewswire)
May-15-24 08:55PM	SPRO Stock Earnings: Spero Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update (GlobeNewswire)
May-08-24 08:00AM	Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024 (GlobeNewswire)
May-01-24 04:07PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.80%
Apr-16-24 11:52AM	14 Cheap Penny Stocks to Buy According to Analysts (Insider Monkey)
Mar-15-24 12:51PM	Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 06:33AM	Q4 2023 Spero Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-13-24 05:10PM	Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates (Zacks)
04:01PM	Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update (GlobeNewswire)
Mar-06-24 08:05AM	Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024 (GlobeNewswire)
Feb-28-24 08:05AM	Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections (GlobeNewswire)
Feb-26-24 08:05AM	Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference (GlobeNewswire)
Feb-05-24 11:27PM	Spero Therapeutics Inc CEO Sath Shukla Sells 75,994 Shares (GuruFocus.com)
Jan-31-24 04:05PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-29-24 04:07AM	15 Cash-Rich Penny Stocks Hedge Funds Are Buying (Insider Monkey)
Jan-25-24 04:40AM	11 Hyper-Growth Stocks Billionaires Are Loading Up On (Insider Monkey)
Jan-05-24 08:05AM	Spero Therapeutics Provides Corporate Update and 2024 Outlook (GlobeNewswire)
Jan-02-24 08:05AM	Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections (GlobeNewswire)
Nov-14-23 09:02AM	Spero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 04:05PM	Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update (GlobeNewswire)
Nov-06-23 08:05AM	Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023 (GlobeNewswire)
Nov-01-23 04:05PM	Spero Therapeutics to Present at Upcoming November Investor Conferences (GlobeNewswire) +5.56%
08:05AM	Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer (GlobeNewswire)
Oct-31-23 04:05PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-18-23 12:00PM	All You Need to Know About Spero Therapeutics, Inc. (SPRO) Rating Upgrade to Buy (Zacks)
Sep-29-23 04:05PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-20-23 04:05PM	Spero Therapeutics to Present at Cantors Global Healthcare 2023 Investor Conference (GlobeNewswire)
Sep-16-23 01:01PM	Insider Sell: Chief Medical Officer Kamal Hamed Sells 39,496 Shares of Spero Therapeutics Inc (GuruFocus.com)
Sep-12-23 08:00AM	Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors (GlobeNewswire)
Sep-06-23 08:05AM	Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-31-23 04:05PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-29-23 12:00PM	Spero Therapeutics, Inc. (SPRO) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) +8.73%
Aug-22-23 05:45PM	Down -11.72% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround (Zacks)
Aug-13-23 05:24AM	Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 06:32AM	Q2 2023 Spero Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 06:05PM	Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update (GlobeNewswire)
Aug-03-23 08:05AM	Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 (GlobeNewswire)
Jul-31-23 08:05AM	Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr (GlobeNewswire) +14.79%
Jul-05-23 06:20AM	Investors in Spero Therapeutics (NASDAQ:SPRO) have unfortunately lost 90% over the last three years (Simply Wall St.)
Jun-30-23 04:05PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-18-23 07:51PM	Strength Seen in TELA Bio, Inc. (TELA): Can Its 11.4% Jump Turn into More Strength? (Zacks)
Jun-14-23 08:05AM	Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer (GlobeNewswire) -5.81%
May-31-23 04:05PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-18-23 07:09AM	Time To Worry? Analysts Are Downgrading Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Outlook (Simply Wall St.)
May-16-23 11:36AM	Spero Therapeutics, Inc. (NASDAQ:SPRO) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-12-23 05:30AM	Q1 2023 Spero Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-11-23 05:35PM	Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update (GlobeNewswire)
May-04-23 08:05AM	Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 (GlobeNewswire)
Apr-28-23 04:05PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-26-23 08:05AM	Spero Therapeutics to Present at Upcoming Investor Conference (GlobeNewswire)
Apr-17-23 07:14AM	Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Right But Growth Is Lacking After Shares Rocket 26% (Simply Wall St.)

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Keutzer Timothy	Chief Operating Officer	Feb 05 '25	Sale	0.78	56,537	44,099	741,439	Feb 05 09:04 PM
Rajavelu Esther	CFO & CBO	Feb 05 '25	Sale	0.78	20,689	16,137	724,720	Feb 05 08:52 PM
Shukla Sath	CEO & President	Feb 05 '25	Sale	0.78	155,333	121,160	1,736,883	Feb 05 08:31 PM
Mahadevia Ankit	Director	Feb 05 '25	Sale	0.78	69,219	53,991	689,866	Feb 05 08:30 PM
Rajavelu Esther	CFO & CBO	Nov 07 '24	Sale	1.31	23,351	30,590	396,515	Nov 12 04:05 PM
Rajavelu Esther	CFO & CBO	Nov 08 '24	Sale	1.30	17,245	22,418	379,270	Nov 12 04:05 PM
Mahadevia Ankit	Director	Aug 27 '24	Sale	1.35	5,912	7,981	759,085	Aug 29 06:43 PM
Keutzer Timothy	Chief Operating Officer	Aug 27 '24	Sale	1.35	2,213	2,988	531,837	Aug 29 06:42 PM
Shukla Sath	CEO & President	Aug 27 '24	Sale	1.35	2,757	3,722	1,140,809	Aug 29 06:36 PM
Shukla Sath	CEO and President	Aug 05 '24	Sale	1.31	17,641	23,110	1,143,566	Aug 06 07:56 PM
Shukla Sath	CEO and President	Aug 02 '24	Sale	1.32	14,800	19,536	1,161,207	Aug 06 07:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SPRO

Spero Therapeutics Inc

Upgrade your FINVIZ experience